Small-molecule tyrosine kinase inhibitors (TKIs) [54], such as imatinib, dasatinib, nilotinib and ponatinib, have been developed to treat CML by blocking the kinase structural domain of the BCR-ABL oncoprotein. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.